search
Back to results

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

Primary Purpose

Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
OA-235i (4 mg)
OA-235i (8 mg)
OA-235i Dose 3
OA-235i Escalating Dose 4
OA-235i Escalating Dose 5
OA-235i Multiple Dose
Sponsored by
Oasis Pharmaceuticals, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Nonalcoholic Steatohepatitis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria: Male and female subjects between the ages of 18 and 70 years, inclusive, at Screening. Body mass index (BMI) of ≥25 and <40 kg/m2 with a total body weight 50-150 kg (inclusive) at Screening and Day 1 Pre-dose. Suspected or confirmed diagnosis of noncirrhotic NAFLD/NASH without advanced hepatic fibrosis by one of the following: Histologically with liver biopsy within 2 years prior to Screening (documentation with pathology report); or Radiologically with ≥5% steatosis measured by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), or controlled attenuation parameter (CAP) >288 dB/m via FibroScan assessment, or presence of hepatic steatosis on abdominal ultrasound within 1 year prior to Screening; or Clinically with a diagnosis of Metabolic Syndrome (MetS) reflecting the presence of at least 3 of 5 factors/criteria (ie, abdominal obesity, elevated triglycerides, reduced HDL-C, elevated blood pressure, and/or elevated fasting glucose [IFG or type 2 diabetes mellitus]) as defined by the National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) [Grundy 2005]; and fatty liver on imaging within 1 year prior to Screening. Key Exclusion Criteria: History or presence of cirrhosis as assessed by Investigator following review of diagnostic measures (clinical, imaging, histopathology, or laboratory). Clinical evidence of hepatic decompensation (laboratory or clinical abnormalities- ascites, variceal bleeding, etc.). History or presence of other concomitant liver disease (eg, hepatitis B & C, alcoholic liver disease, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin (A1AT) deficiency, bile duct obstruction, liver primary or metastatic cancer, drug-induced liver disease.

Sites / Locations

  • Mayo ClinicRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

OA-235i (4-40 mg)

Arm Description

Single ascending dose (SAD): OA-235i (4-40 mg) administered subcutaneously (SC) once to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis. Multiple dose (MD): OA-235i (dose level to be determined from SAD) administered subcutaneously (SC) once daily for 7 days to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis.

Outcomes

Primary Outcome Measures

Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with treatment-emergent with adverse events (incidence and severity)

Secondary Outcome Measures

To characterize the OA-235i Pharmacokinetics (PK) by Cmax
OA-235i PK by peak plasma concentration (Cmax)
To characterize the OA-235i Pharmacokinetics (PK) by t1/2
OA-235i PK by the terminal elimination half-life (t1/2)
To characterize the OA-235i Pharmacokinetics (PK) by Tmax
OA-235i PK by time to peak plasma concentration (Tmax)
To characterize the OA-235i Pharmacokinetics (PK) by AUC
OA-235i PK by area under the plasma concentration versus time curve (AUC)

Full Information

First Posted
December 12, 2022
Last Updated
September 5, 2023
Sponsor
Oasis Pharmaceuticals, LLC
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT05680233
Brief Title
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
Official Title
A Phase 1a/1b Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OA-235i, a PAR2 Inhibitor, in Adults With Nonalcoholic Steatohepatitis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 23, 2023 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oasis Pharmaceuticals, LLC
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a Phase 1, first-in-human single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of OA-235i in subjects with nonalcoholic steatohepatitis.
Detailed Description
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single ascending dose (SAD) in participants with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis. This dose-escalating strategy will test the safety of OA-235i when given as a single subcutaneous dosage using up to five successive cohorts. Each cohort will have three non-randomized participants receiving the active medication. One (1) planned multiple dose (MD) expansion dose cohort with 8 NAFLD/NASH subjects will be enrolled for a 7-day dosing regimen at a dose level to be determined from the SAD portion of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Single ascending dose (SAD) sequential group study of a sc dose of OA-235i in five (5) planned dose cohorts with 3 subjects/cohort administering a bolus injection at escalating dose levels from 4 to 40 mg. One (1) planned multiple dose (MD) expansion dose cohort with 8 NAFLD/NASH subjects will be enrolled for a 7-day dosing regimen at a dose level to be determined from the SAD portion of the study.
Masking
None (Open Label)
Masking Description
All subjects will be blinded to IP dose/level.
Allocation
N/A
Enrollment
23 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
OA-235i (4-40 mg)
Arm Type
Experimental
Arm Description
Single ascending dose (SAD): OA-235i (4-40 mg) administered subcutaneously (SC) once to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis. Multiple dose (MD): OA-235i (dose level to be determined from SAD) administered subcutaneously (SC) once daily for 7 days to adult subjects with suspected or confirmed diagnosis of noncirrhotic nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) without advanced hepatic fibrosis.
Intervention Type
Drug
Intervention Name(s)
OA-235i (4 mg)
Other Intervention Name(s)
PAR2 inhibitor
Intervention Description
3 participants will receive 4 mg as a single subcutaneous dose
Intervention Type
Drug
Intervention Name(s)
OA-235i (8 mg)
Other Intervention Name(s)
PAR2 inhibitor
Intervention Description
3 participants will receive 8 mg as a single subcutaneous dose
Intervention Type
Drug
Intervention Name(s)
OA-235i Dose 3
Other Intervention Name(s)
PAR2 inhibitor
Intervention Description
3 participants will receive a single escalating subcutaneous dose
Intervention Type
Drug
Intervention Name(s)
OA-235i Escalating Dose 4
Other Intervention Name(s)
PAR2 inhibitor
Intervention Description
3 participants will receive a single escalating subcutaneous dose
Intervention Type
Drug
Intervention Name(s)
OA-235i Escalating Dose 5
Other Intervention Name(s)
PAR2 inhibitor
Intervention Description
3 participants will receive a single escalating subcutaneous dose
Intervention Type
Drug
Intervention Name(s)
OA-235i Multiple Dose
Other Intervention Name(s)
PAR2 inhibitor
Intervention Description
8 participants will receive a daily subcutaneous dose for 7 consecutive days
Primary Outcome Measure Information:
Title
Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Description
Number of participants with treatment-emergent with adverse events (incidence and severity)
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
To characterize the OA-235i Pharmacokinetics (PK) by Cmax
Description
OA-235i PK by peak plasma concentration (Cmax)
Time Frame
8 Days
Title
To characterize the OA-235i Pharmacokinetics (PK) by t1/2
Description
OA-235i PK by the terminal elimination half-life (t1/2)
Time Frame
8 Days
Title
To characterize the OA-235i Pharmacokinetics (PK) by Tmax
Description
OA-235i PK by time to peak plasma concentration (Tmax)
Time Frame
8 Days
Title
To characterize the OA-235i Pharmacokinetics (PK) by AUC
Description
OA-235i PK by area under the plasma concentration versus time curve (AUC)
Time Frame
8 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Male and female subjects between the ages of 18 and 70 years, inclusive, at Screening. Body mass index (BMI) of ≥25 and <40 kg/m2 with a total body weight 50-150 kg (inclusive) at Screening and Day 1 Pre-dose. Suspected or confirmed diagnosis of noncirrhotic NAFLD/NASH without advanced hepatic fibrosis by one of the following: Histologically with liver biopsy within 2 years prior to Screening (documentation with pathology report); or Radiologically with ≥5% steatosis measured by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF), or controlled attenuation parameter (CAP) >288 dB/m via FibroScan assessment, or presence of hepatic steatosis on abdominal ultrasound within 1 year prior to Screening; or Clinically with a diagnosis of Metabolic Syndrome (MetS) reflecting the presence of at least 3 of 5 factors/criteria (ie, abdominal obesity, elevated triglycerides, reduced HDL-C, elevated blood pressure, and/or elevated fasting glucose [IFG or type 2 diabetes mellitus]) as defined by the National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) [Grundy 2005]; and fatty liver on imaging within 1 year prior to Screening. Key Exclusion Criteria: History or presence of cirrhosis as assessed by Investigator following review of diagnostic measures (clinical, imaging, histopathology, or laboratory). Clinical evidence of hepatic decompensation (laboratory or clinical abnormalities- ascites, variceal bleeding, etc.). History or presence of other concomitant liver disease (eg, hepatitis B & C, alcoholic liver disease, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin (A1AT) deficiency, bile duct obstruction, liver primary or metastatic cancer, drug-induced liver disease.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Manal Abdelmalek, MD
Phone
507-284-2511
Email
Abdelmalek.manal@mayo.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Christopher Kigongo
Phone
507-226-1998
Email
Kigongo.Christopher@mayo.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Athan Kuliopulos, MD, PhD
Organizational Affiliation
Oasis Pharmaceuticals, LLC
Official's Role
Study Director
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manal Abdelmalek, MD
Phone
507-284-2511
Email
Abdelmalek.manal@mayo.edu
First Name & Middle Initial & Last Name & Degree
Christopher Kigongo
Phone
507-226-1998
Email
Kigongo.Christopher@mayo.edu

12. IPD Sharing Statement

Learn more about this trial

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

We'll reach out to this number within 24 hrs